Introducing Relfydess™: Galderma’s First And Only Ready-To-Use Liquid Neuromodulator

Galderma is making waves with the launch of Relfydess™ (RelabotulinumtoxinA), the first and only ready-to-use liquid neuromodulator. Powered by PEARL™ Technology, this groundbreaking addition is set to transform injectable treatments for frown lines and crow’s feet, providing superior efficacy and convenience for both patients and practitioners.

Photo Credit: Courtesy of RESTOCK Images/Shutterstock

Clinical Excellence Backed by READY Trials

At the forefront of this innovative advancement is Sachin M. Shridharani, MD, FACS, the lead investigator for the Relfydess™ clinical trials, including the READY program. This phase III clinical trial series enrolled over 1,900 participants, exploring the safety, rapid onset, and sustained effectiveness of this next-generation neuromodulator.

The READY trials delivered impressive results:

• In READY-1 and READY-2, 96.3% of participants experienced none-to-mild frown lines, while 87.2% saw similar improvement for crow’s feet after one month. In comparison, placebo rates were 4.5% and 11.9%, respectively.
• Relfydess™ showed an onset of action as early as day one, with 39% of patients reporting improvements in frown lines and 34% in crow’s feet within the first 24 hours.
• These results were sustained over time, with up to 75% of participants maintaining visible improvements for six months.

A Leap Forward in Injectable Aesthetics

What sets Relfydess™ apart from other neuromodulators is the PEARL™ Technology, designed to preserve molecular integrity while offering a complex-free, highly active molecule. This enables consistent results with a simple volumetric dosing system, eliminating the need for reconstitution. As part of Galderma's robust injectable portfolio, Relfydess™ aims to enhance the practitioner’s ability to deliver precise, reliable treatments every time.

Broader Approvals and Market Availability

Once national approvals are finalized, Relfydess™ will be the first neuromodulator in Europe to receive initial approval for two indications—frown lines and crow’s feet—simultaneously. The product has already secured marketing authorization from Australia’s Therapeutic Goods Administration (TGA), showcasing its global potential in aesthetic medicine.

As Galderma continues to push the boundaries of injectable aesthetics, Relfydess™ is set to revolutionize the way we treat expression lines. With rapid onset, long-lasting results, and enhanced patient satisfaction, this ready-to-use neuromodulator is poised to become a go-to solution for those seeking effective, non-invasive cosmetic enhancements.

With Dr. Shridharani leading the charge, the future of aesthetic treatments looks brighter than ever.

For more information, visit Sachin Shridharani, MD, FACS's social media: